Probiodrug Ag

Torsten Hoffman

Hans-Ulrich Demuth

Ulrich Heiser

Stephan Schilling

Mirko Buchholz

Andre Johannes Niestroj

Michael Thormann

Andreas Treml

Michael Almstetter

Holger Cynis

Robert Sommer

Ulf-Torsten Gaertner

Antje Hamann

Compounds of general formula (I): wherein R, R, R, R, X and Y are as defined herein are inhibitors of glutaminyl cyclase and are therefore useful in treating conditions that can be treated by modulation of glutaminyl cyclase activity.

Inhibitors of glutaminyl cyclase

Provided herein are methods for the treatment and/or prevention of an inflammatory disease or disorder through administration of an inhibitor of a glutaminyl peptide cyclotransferase. Inflammatory diseases or disorders treated or prevented by methods disclosed herein include mild cognitive impairment (MCI), rheumatoid arthritis, atherosclerosis, restenosis and pancreatitis.

Method of treating inflammation with glutaminyl cyclase inhibitors

The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC, methods for screening for such effectors, and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of conditions that can be treated by modulation of QC-activity. Preferred compositions additionally comprise inhibitors of DP IV or DP IV-like enzymes for the treatment or alleviation of conditions that can be treated by modulation of QC- and DP IV-activity.

Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases

Growing community of inventors

Halle/Saale, Germany

Torsten Hoffman